The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...
The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.
FDA moves to strike suicide risk warnings from Saxenda, Wegovy, and Zepbound labels after analysis finds no increased risk.
(CNN)– The Food and Drug Administration (FDA) wants suicide warnings to be taken off of some popular weight-loss medications.
The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts ...
Pharmaceutical Technology on MSN
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also ...
US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased ...
The Food and Drug Administration (FDA) is seeking to remove suicide warnings from several popular weight-loss medications, including Wegovy, Zepbound and Saxenda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results